Literature DB >> 11237472

CPEB degradation during Xenopus oocyte maturation requires a PEST domain and the 26S proteasome.

C G Reverte1, M D Ahearn, L E Hake.   

Abstract

Cytoplasmic poly(A) elongation is widely utilized during the early development of many organisms as a mechanism for translational activation. Targeting of mRNAs for this mechanism requires the presence of a U-rich element, the cytoplasmic polyadenylation element (CPE), and its binding protein, CPEB. Blocking cytoplasmic polyadenylation by interfering with the CPE or CPEB prevents the translational activation of mRNAs that are crucial for oocyte maturation. The CPE sequence and CPEB are also important for translational repression of mRNAs stored in the Xenopus oocyte during oogenesis. To understand the contribution of protein metabolism to these two roles for CPEB, we have examined the mechanisms influencing the expression of CPEB during oogenesis and oocyte maturation. Through a comparison of CPEB mRNA levels, protein synthesis, and accumulation, we find that CPEB is synthesized during oogenesis and stockpiled in the oocyte. Minimal synthesis of CPEB, <3.6%, occurs during oocyte maturation. In late oocyte maturation, 75% of CPEB is degraded coincident with germinal vesicle breakdown. Using proteasome and ubiquitination inhibitors, we demonstrate that CPEB degradation occurs via the proteasome pathway, most likely through ubiquitin-conjugated intermediates. In addition, we demonstrate that degradation requires a 14 amino acid PEST domain. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11237472     DOI: 10.1006/dbio.2001.0153

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  37 in total

1.  A novel karyoskeletal protein: characterization of protein NO145, the major component of nucleolar cortical skeleton in Xenopus oocytes.

Authors:  S Kneissel; W W Franke; J G Gall; H Heid; S Reidenbach; M Schnölzer; H Spring; H Zentgraf; M S Schmidt-Zachmann
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

2.  Differential mRNA translation and meiotic progression require Cdc2-mediated CPEB destruction.

Authors:  Raul Mendez; Daron Barnard; Joel D Richter
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

3.  Meiosis requires a translational positive loop where CPEB1 ensues its replacement by CPEB4.

Authors:  Ana Igea; Raúl Méndez
Journal:  EMBO J       Date:  2010-06-08       Impact factor: 11.598

4.  RFPL4 interacts with oocyte proteins of the ubiquitin-proteasome degradation pathway.

Authors:  Nobuhiro Suzumori; Kathleen H Burns; Wei Yan; Martin M Matzuk
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-13       Impact factor: 11.205

5.  The active form of Xp54 RNA helicase in translational repression is an RNA-mediated oligomer.

Authors:  Nicola Minshall; Nancy Standart
Journal:  Nucleic Acids Res       Date:  2004-02-24       Impact factor: 16.971

6.  Mechanism of degradation of CPEB during Xenopus oocyte maturation.

Authors:  Daiki Setoyama; Masakane Yamashita; Noriyuki Sagata
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

7.  Enforcing temporal control of maternal mRNA translation during oocyte cell-cycle progression.

Authors:  Karthik Arumugam; Yiying Wang; Linda L Hardy; Melanie C MacNicol; Angus M MacNicol
Journal:  EMBO J       Date:  2009-12-03       Impact factor: 11.598

Review 8.  Translational control in oocyte development.

Authors:  Joel D Richter; Paul Lasko
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-09-01       Impact factor: 10.005

9.  The RNA binding protein CPEB regulates dendrite morphogenesis and neuronal circuit assembly in vivo.

Authors:  Jennifer E Bestman; Hollis T Cline
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

10.  An unusual two-step control of CPEB destruction by Pin1.

Authors:  Morris Nechama; Chien-Ling Lin; Joel D Richter
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.